The US Court of Appeals for the Federal Circuit has quashed an appeal from the Takeda (TYO: 4502) unit Baxalta in relation to Roche’s (ROG: SIX) hemophilia treatment Hemlibra (emicizumab).
Baxalta had claimed that the blockbuster product infringed one of its patents, saying that Hemlibra copies its patented antibodies in the way that it clots blood.
The District Court for the District of Delaware last year found that the relevant parts of Baxalta's patent were invalid, denying the company’s compensation claim and its demand that Roche stop selling Hemlibra in the USA until the patent had expired.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze